

ARES ALLERGY HOLDINGS PLC

ARES ALLERGY HOLDINGS PLC UPDATES ON THE DEVELOPMENT OF ITS HOUSE DUST MITE SUBLINGUAL IMMUNOTHERAPY TABLET IN ALLERGIC ASTHMA

London (United Kingdom), 23 October 2015 – Ares Allergy Holdings plc (Stallergenes Greer) (Euronext: STAGR) today provides an update on the development of its house dust mite (“HDM”) sublingual immunotherapy tablet (STG320) for the treatment of allergic asthma.

A phase II study investigating the efficacy and safety of sublingual immunotherapy tablets of HDM allergen extracts in adults with HDM associated allergic asthma was conducted in 11 European countries with 386 randomized patients (study VO72.12). Although the study did not meet its primary endpoint (effect of treatment as compared to placebo on the Asthma Control Test™ score), the HDM sublingual tablet was shown to be active with clear evidence of a dose response based on its immunological activity. No unexpected adverse events were observed.

Dr. Robert K. Zeldin, Ares Allergy Head of Clinical Development, stated:

“The trial has produced a comprehensive dataset which is undergoing review to determine the next development steps. We continue to be focused on implementing our innovation-based strategy and are committed to delivering effective treatments for patients living with allergic asthma and other allergic diseases.”

Professor Pascal Demoly, from the University Hospital of Montpellier, France, the principal investigator for the VO72.12 study, commented:

“This is an important milestone in Ares Allergy’s development program for HDM immunotherapy. The VO72.12 study has demonstrated that the HDM sublingual tablet is an active compound, with clear dose dependent immune response.”

ABOUT THE VO72.12 STUDY (ALLERGIC ASTHMA)

This was a randomized, double-blind, placebo-controlled, dose ranging trial to assess the efficacy and safety of house dust mite sublingual immunotherapy tablets for the treatment of allergic asthma. Adults aged 18 to 50 years with medical history consistent with house dust mite-induced allergic asthma and rhinitis were eligible. A total of 386 patients from 11 European countries were randomized to receive 1 year of treatment with house dust mite sublingual immunotherapy tablets or placebo.

ABOUT ARES ALLERGY HOLDINGS PLC

Headquartered in London (UK), Ares Allergy Holdings plc is a global company specialising in the diagnosis and treatment of allergies through the development and commercialization of allergy immunotherapy products and services. Ares Allergy Holdings plc is the parent company of GREER Laboratories, Inc. (whose registered office is in the U.S.) and STALLERGENES SAS (whose registered office is in France).

Trading information:

Name: Stallergenes Greer

ISIN: GB00BZ21RF93 1 - Ticker: STAGR

ICB classification: 4577

Market: Euronext Paris regulated market

Additional information is available at <http://www.aresallergy.com>

Contacts:

Investor and analyst relations

Peter Bühler

Chief Financial Officer

Tel: +33 1 55 59 23 22

Email: investorrelations@aresallergyco.com

Media relations

Lise Lemonnier

Head of Global Communications

Tel: + 33 1 55 59 20 96

Email: llemonnier@stallergenes.com

Investor and Media relations agency

UK: Robin Wrench, Brunswick Group

Email: aresallergy@brunswickgroup.com

Tel. +44 (0)20 7404 5959